Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China

  1. Yao Wu
  2. Libo Tao
  3. Chang Liu
  4. Fangxu Wang
  5. Shuang Sun
Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1007/s11096-025-01865-8
  2. Version published to 10.21203/rs.3.rs-5061949/v1 on Research Square